Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Has The Lipid Disorder Treatment Market Size Shifted, And What Is the Outlook Through 2034?

The market size of treatments for lipid disorders has seen swift expansion in the past few years. Predictions suggest it will inflate from $10.69 billion in 2024 to $12.09 billion in 2025, boasting a compound annual growth rate (CAGR) of 13.2%. The growth in past years is linked to several factors such as the growth in sedentary lifestyle adoption, expanding working population, escalating awareness about the disease and its treatments, increased number of desk jobs, and the rise in instances of familial combined hyperlipidemia.

How Much Will the Lipid Disorder Treatment Market Be Worth in 2029?

In the coming years, the market size for lipid disorder treatment is set to witness a dramatic surge, reaching $19.56 billion in 2029 with a compound annual growth rate (CAGR) of 12.8%. This growth during the forecast period can be credited to the escalating obesity and high cholesterol cases, increased instances of cardiovascular diseases, and the rising incidence of heart diseases triggered by high cholesterol. The surge in demand for effective and safe therapies, as well as widespread alcohol consumption and smoking also contribute to this growth. Significant trends during the forecast period comprise of technological progression in drug development, product innovation, amplified investments for business expansion, technological enhancements in treatment facilities, and clinical advancements.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15600&type=smp

Which is the Largest Company in the Lipid Disorder Treatment Market?

Major companies operating in the lipid disorder treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi S.A., AstraZeneca Plc, Fresenius SE & Co. KGaA, Abbott Laboratories Inc., Novartis AG, GlaxoSmithKline Plc, Wockhardt Ltd., Eli Lilly and Company, Amgen Inc., Boehringer-Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Kaneka Corporation, Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Emcure Pharmaceuticals Limited, Kowa Pharmaceuticals America Inc., Concord Biotech Limited, Biocon Ltd., Ranbaxy Laboratories Limited

What Are the Main Market Drivers in the Lipid Disorder Treatment Industry?

The escalating incidences of obesity and high-cholesterol conditions are predicted to spur the lipid disorder treatment market’s expansion. Obesity is defined as an excessive accumulation of body fat, and high cholesterol corresponds to increased cholesterol levels in the blood, both of which pose substantial health hazards. Unhealthy eating habits, a lack of physical activity, genetic factors, and environmental factors are the different causes of obesity and high cholesterol. Treatment of lipid disorders is crucial in managing these conditions, as it melds pharmacological approaches with lifestyle changes, weight management techniques, patient awareness, and multidisciplinary healthcare. For instance, the World Obesity Atlas 2022, published in May 2022 by the World Obesity Federation – a non-profit organization based in the UK – reported that one billion people worldwide, including 1 in 5 women and 1 in 7 men, will be struggling with obesity by 2030. This number is expected to rise to 4 billion, which equates to 51% of the global population by 2035. Thus, the escalating incidences of obesity and high cholesterol are stimulating the expansion of the lipid disorder treatment market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=15600&type=smp

How Is the Lipid Disorder Treatment Market Segments Structured?

The lipid disorder treatment market covered in this report is segmented –

1) By Drug Type: Atorvastatin, Fluvastatin, Rosuvastatin, Simvastatin, Pravastatin, Other Drugs

2) By Indication: Familial Combined Hyperlipidemia, Familial Defective Apolipoprotein B-100, Familial Dysbetalipoproteinemia, Familial Hypertriglyceridemia, Heterozygous Familial Hypercholesterolemia, Other Indications

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Atorvastatin: Generic Atorvastatin, Brand-Name Atorvastatin ( Lipitor)

2) By Fluvastatin: Generic Fluvastatin, Brand-Name Fluvastatin ( Lescol)

3) By Rosuvastatin: Generic Rosuvastatin, Brand-Name Rosuvastatin ( Crestor)

4) By Simvastatin: Generic Simvastatin, Brand-Name Simvastatin ( Zocor)

5) By Pravastatin: Generic Pravastatin, Brand-Name Pravastatin ( Pravachol)

6) By Other Drugs: Ezetimibe, Pcsk9 Inhibitors ( Alirocumab, Evolocumab), Fibrates ( Gemfibrozil, Fenofibrate), Niacin (Vitamin B3), Omega-3 Fatty Acids ( Icosapent Ethyl)

What Strategic Trends Are Transforming the Lipid Disorder Treatment Market?

Numerous leading firms in the lipid disorder treatment market are focusing on the development of proprotein convertase subtilisin type 9 (PCSK9) inhibitors to meet the increasing demand for more efficient and specific treatments for high cholesterol levels. By boosting the elimination of LDL cholesterol from the blood, PCSK9 inhibitors can effectively manage lipid disorders and decrease the likelihood of cardiovascular incidents in patients at high risk. For example, in March 2024, Regeneron Pharmaceuticals Inc., a Biotechnology Company based in the United States, secured approval for the Praluent (alirocumab) injection authorized by U.S. Food and Drug Administration (FDA) for use in heterozygous familial hypercholesterolemia (HeFH) in children aged 8 and older. Praluent injection distinguishes itself with its capability to hinder the PCSK9 from binding to the LDL receptor, thereby multiplying the number of LDL receptors on the liver cells surfaces. This process ultimately helps in the removal of LDL and decreases LDL-C levels in the blood.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/lipid-disorder-treatment-global-market-report

Which Global Regions Offer the Highest Growth in the Lipid Disorder Treatment Market?

North America was the largest region in the lipid disorder treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lipid disorder treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15600

This Report Delivers Insight On:

1. How big is the lipid disorder treatment market, and how is it changing globally?

2. Who are the major companies in the lipid disorder treatment market, and how are they performing?

3. What are the key opportunities and risks in the lipid disorder treatment market right now?

4. Which products or customer segments are growing the most in the lipid disorder treatment market?

5. What factors are helping or slowing down the growth of the lipid disorder treatment market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.